Setileuton, formerly known as MK0633, is a potent and selective 5-lipoxygenase inhibitor which is under investigation for the treatment of asthma and atherosclerosis. References: Maciolek CM, Ma B, Menzel K, Laliberte S, Bateman K, Krolikowski P, Gibson CR. Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2011 May;39(5):763-70. doi: 10.1124/dmd.110.037366. Epub 2011 Feb 16. PubMed PMID: 21325431.

纯度：≥98%

CAS：910656-27-8